NBSE
Closed
Neubase Therapeutics Inc
0.378
0.000 (0.00%)
Last Update: 24 May 2024 16:30:00
Yesterday: 0.378
Day's Range: 0.378 - 0.378
Send
sign up or login to leave a comment!
When Written:
0.1693
NeuBase Therapeutics Inc. is a biotechnology company that is focused on developing therapies for a variety of genetic diseases. The company's proprietary technology platform, called PATrOL™, is designed to enable the development of highly specific and effective therapies that target genetic mutations at the RNA level. NeuBase's lead product candidate is a treatment for Huntington's disease, a genetic disorder that affects the brain and nervous system. The company is also developing therapies for other genetic diseases, including myotonic dystrophy and familial amyloidosis. NeuBase is headquartered in Pittsburgh, Pennsylvania and was founded in 2018.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








